JAMD – Online il volume 26 – n. 1
Leggi
All‐cause mortality and cardiovascular outcomes with sodium‐glucose Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes
Riley DR, Essa H, Austin P, et al.
Diabetes Obes Metab. Pub. online 29 Jun 2023.
Leggi
Diabetic foot ulcers: a review
Armstrong DG, Tan TW, Boulton AJM, et al.
JAMA. 2023;330(1):62-75.
Leggi
Health and economic impact of improved glucose, blood pressure and lipid control among German adults with type 2 diabetes: a modelling study
Fan M, Stephan AJ, Emmert-Fees K, et al.
Diabetologia. Pub. online 30 Jun 2023.
Leggi
Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial
Doi Y, Hamano T, Yamaguchi S, et al.
Diabetes Obes Metab. Pub. online 29 Jun 2023.
Leggi
A comparison of faster insulin aspart to standard insulin aspart using hybrid automated insulin delivery system in active children and adolescents with type 1 diabetes: a randomized, double-blind crossover trial
Dovc K, Bergford S, Fröhlich-Reiterer E, et al.
Diabetes Technol Ther. Pub. online 5 Jul 2023.
Leggi
Diabetes remission in drug‐naïve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study
Zeng J, Gan S, Mi N, et al.
Diabetes Obes Metab. Pub. online 29 Jun 2023.
Leggi
Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial
Zhang L, Zhang Y, Shen S, et al.
Lancet Diabetes Endocrinol. 2023;S2213-8587(23)00132-8.
Leggi